002252 上海莱士
午间休市 08-26 11:30:00
资讯
新帖
简况
股市必读:上海莱士新发布《2026年半年度报告》
证券之星 · 05:27
股市必读:上海莱士新发布《2026年半年度报告》
上海莱士(002252)披露聘任财务负责人公告,8月25日股价上涨1.87%
证券之星 · 08-25 18:57
上海莱士(002252)披露聘任财务负责人公告,8月25日股价上涨1.87%
上海莱士最新公告:上半年净利润6.61亿元同比下降35.8%
证券之星 · 08-24 23:31
上海莱士最新公告:上半年净利润6.61亿元同比下降35.8%
上海莱士(002252)披露全资子公司“蛋白C”临床试验申请获得受理的公告,8月24日股价下跌0.21%
证券之星 · 08-24 18:12
上海莱士(002252)披露全资子公司“蛋白C”临床试验申请获得受理的公告,8月24日股价下跌0.21%
上海莱士:全资子公司“蛋白C”临床试验申请获受理 目前国内尚无同类人蛋白C制剂获批上市
格隆汇 · 08-21
上海莱士:全资子公司“蛋白C”临床试验申请获受理 目前国内尚无同类人蛋白C制剂获批上市
股市必读:上海莱士(002252)股东户数11.74万户,较上期减少0.3%
证券之星 · 08-20
股市必读:上海莱士(002252)股东户数11.74万户,较上期减少0.3%
上海莱士:目前公司浆源底盘稳固,营销改革持续推进,渠道库存逐步优化,创新药管线有序推进
证券之星 · 08-19
上海莱士:目前公司浆源底盘稳固,营销改革持续推进,渠道库存逐步优化,创新药管线有序推进
股市必读:上海莱士(002252)股东户数11.78万户,较上期减少2.74%
证券之星 · 08-14
股市必读:上海莱士(002252)股东户数11.78万户,较上期减少2.74%
上海莱士:截至2026年7月31日,公司股东总户数为117,773户
证券之星 · 08-13
上海莱士:截至2026年7月31日,公司股东总户数为117,773户
股市必读:上海莱士新发布《关于第六届董事会第二十次(临时)会议决议公告》
证券之星 · 08-13
股市必读:上海莱士新发布《关于第六届董事会第二十次(临时)会议决议公告》
股市必读:上海莱士新发布《关于第六届董事会第二十次(临时)会议决议公告》
证券之星 · 08-12
股市必读:上海莱士新发布《关于第六届董事会第二十次(临时)会议决议公告》
上海莱士(002252)披露拟续聘2026年度会计师事务所公告,8月11日股价下跌0.8%
证券之星 · 08-11
上海莱士(002252)披露拟续聘2026年度会计师事务所公告,8月11日股价下跌0.8%
股市必读:上海莱士(002252)8月7日董秘有最新回复
证券之星 · 08-10
股市必读:上海莱士(002252)8月7日董秘有最新回复
上海莱士新提交“-”、“莱莱侠”等2件商标注册申请
证券之星 · 08-07
上海莱士新提交“-”、“莱莱侠”等2件商标注册申请
上海莱士:公司7月推出的回购方案将全部用于注销并减少注册资本
证券之星 · 07-30
上海莱士:公司7月推出的回购方案将全部用于注销并减少注册资本
上海莱士(002252)7月20日股东户数12.11万户,较上期增加2.01%
证券之星 · 07-30
上海莱士(002252)7月20日股东户数12.11万户,较上期增加2.01%
上海莱士:截至2026年7月20日,公司股东总户数为121,087户
证券之星 · 07-30
上海莱士:截至2026年7月20日,公司股东总户数为121,087户
公司问答丨上海莱士:公司拥有SR604中国大陆、中国香港地区及中国台湾地区研发、商业化权益
格隆汇 · 07-24
公司问答丨上海莱士:公司拥有SR604中国大陆、中国香港地区及中国台湾地区研发、商业化权益
上海莱士:SR604抗体来自同一原始细胞株
证券之星 · 07-24
上海莱士:SR604抗体来自同一原始细胞株
上海莱士(002252)披露SR604注射液II期临床试验登记进展,7月22日股价上涨0.78%
证券之星 · 07-22
上海莱士(002252)披露SR604注射液II期临床试验登记进展,7月22日股价上涨0.78%
加载更多
公司概况
公司名称:
上海莱士血液制品股份有限公司
所属行业:
医药制造业
上市日期:
2008-06-23
主营业务:
上海莱士血液制品股份有限公司的主营业务是血液制品的生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品。公司先后获评“上海市外商投资先进技术企业”“高新技术企业”,并设立“院士专家工作站”,彰显在技术研发与质量管控领域的领先地位;公司及旗下南岳生物先后斩获第九届上海市奉贤区区长质量奖金奖和“第八届湖南省省长质量奖”。
发行价格:
12.81
{"stockData":{"symbol":"002252","market":"SZ","secType":"STK","nameCN":"上海莱士","latestPrice":4.94,"timestamp":1787716308000,"preClose":4.9,"halted":0,"volume":39508100,"delay":0,"changeRate":0.0082,"floatShares":6588000000,"shares":6593000000,"eps":0.1833,"marketStatus":"午间休市","change":0.04,"latestTime":"08-26 11:30:00","open":4.9,"high":5,"low":4.89,"amount":196000000,"amplitude":0.0224,"askPrice":4.95,"askSize":1391,"bidPrice":4.94,"bidSize":1343,"shortable":0,"etf":0,"ttmEps":0.1833,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787720400000},"marketStatusCode":3,"adr":0,"adjPreClose":4.9,"symbolType":"stock","openAndCloseTimeList":[[1787707800000,1787715000000],[1787720400000,1787727600000]],"highLimit":5.39,"lowLimit":4.41,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6592672885,"isCdr":false,"pbRate":1,"roa":"--","peRate":26.950355,"roe":"2.04%","epsLYR":0.24,"committee":0.18214,"marketValue":32568000000,"turnoverRate":0.006,"status":0,"floatMarketCap":32546000000},"requestUrl":"/m/hq/s/002252","defaultTab":"news","newsList":[{"id":"2662575737","title":"股市必读:上海莱士新发布《2026年半年度报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662575737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662575737?lang=zh_cn&edition=full","pubTime":"2026-08-26 05:27","pubTimestamp":1787693232,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘,上海莱士报收于4.9元,上涨1.87%,换手率0.71%,成交量46.53万手,成交额2.26亿元。公司公告汇总:第六届董事会第二十一次会议审议通过《2026年半年度报告全文及摘要》及《关于聘任公司财务负责人的议案》,同意聘请江兰女士为财务负责人,任期至第六届董事会期满。股本股东变化股东户数变动截至2026年8月10日公司股东户数为11.74万户,较7月31日减少355.0户,减幅为0.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600008461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002252","BK0196","BK0188","BK0028","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662736413","title":"上海莱士(002252)披露聘任财务负责人公告,8月25日股价上涨1.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662736413","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662736413?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:57","pubTimestamp":1787655473,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘,上海莱士报收于4.9元,较前一交易日上涨1.87%,最新总市值为323.04亿元。该股当日开盘4.8元,最高4.91元,最低4.78元,成交额达2.26亿元,换手率为0.71%。上海莱士血液制品股份有限公司于2026年8月21日召开第六届董事会第二十一次会议,审议通过《2026年半年度报告全文及摘要》和《关于聘任公司财务负责人的议案》。公司董事会同意聘请江兰女士为财务负责人,任期至第六届董事会期满。相关公告文件已在指定媒体及巨潮资讯网披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500040219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002252","BK0046","BK0028","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661277225","title":"上海莱士最新公告:上半年净利润6.61亿元同比下降35.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661277225","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661277225?lang=zh_cn&edition=full","pubTime":"2026-08-24 23:31","pubTimestamp":1787585461,"startTime":"0","endTime":"0","summary":"上海莱士(002252.SZ)发布2026年半年度报告,实现营业收入32.09亿元,同比下降18.79%;归属于上市公司股东的净利润6.61亿元,同比下降35.8%。公司计划不派发现金红利,不送红股,不以公积金转增股本。注:公司Q2净利润3.45亿,Q1净利润3.16亿,据此计算,Q2净利润环比增长9%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400038582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661206402","title":"上海莱士(002252)披露全资子公司“蛋白C”临床试验申请获得受理的公告,8月24日股价下跌0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661206402","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661206402?lang=zh_cn&edition=full","pubTime":"2026-08-24 18:12","pubTimestamp":1787566374,"startTime":"0","endTime":"0","summary":"截至2026年8月24日收盘,上海莱士报收于4.81元,较前一交易日下跌0.21%,最新总市值为317.11亿元。近日,上海莱士披露公告显示,其全资子公司广西莱士生物制药有限公司于2026年8月21日收到国家药品监督管理局下发的关于“蛋白C”临床试验申请的《受理通知书》。临床试验申请已获受理,自受理之日起60日内未收到否定或质疑意见可按方案开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400025970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0188","BK0046","BK0028","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661298331","title":"上海莱士:全资子公司“蛋白C”临床试验申请获受理 目前国内尚无同类人蛋白C制剂获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2661298331","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661298331?lang=zh_cn&edition=full","pubTime":"2026-08-21 20:27","pubTimestamp":1787315256,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","BK0188","BK0239","002252","BK0196","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660422228","title":"股市必读:上海莱士(002252)股东户数11.74万户,较上期减少0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660422228","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660422228?lang=zh_cn&edition=full","pubTime":"2026-08-20 01:09","pubTimestamp":1787159352,"startTime":"0","endTime":"0","summary":"截至2026年8月19日收盘,上海莱士报收于4.89元,上涨0.0%,换手率0.6%,成交量39.32万手,成交额1.92亿元。交易信息汇总资金流向8月19日主力资金净流入2737.99万元,占总成交额14.29%;游资资金净流出2015.28万元,占总成交额10.52%;散户资金净流出722.71万元,占总成交额3.77%。股本股东变化股东户数变动截至2026年8月10日公司股东户数为11.74万户,较7月31日减少355户,减幅为0.3%。户均持股数量由上期的5.6万股增加至5.61万股,户均持股市值为28.19万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000001480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0196","BK0188","002252","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660413959","title":"上海莱士:目前公司浆源底盘稳固,营销改革持续推进,渠道库存逐步优化,创新药管线有序推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2660413959","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660413959?lang=zh_cn&edition=full","pubTime":"2026-08-19 08:39","pubTimestamp":1787099947,"startTime":"0","endTime":"0","summary":"证券之星消息,上海莱士08月18日在投资者关系平台上答复投资者关心的问题。公司全年业绩情况具体请以后续定期报告为准。目前公司浆源底盘稳固,营销改革持续推进,渠道库存逐步优化,创新药管线有序推进。公司的核心价值主要体现在稳固的主业基础、持续深化的内部改革以及创新管线的未来潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900007535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159992","BK0028","BK0196","BK0046","BK1574","002252","BK0239","BK0188","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659694391","title":"股市必读:上海莱士(002252)股东户数11.78万户,较上期减少2.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659694391","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659694391?lang=zh_cn&edition=full","pubTime":"2026-08-14 01:20","pubTimestamp":1786641659,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘,上海莱士报收于5.02元,上涨1.01%,换手率1.01%,成交量66.6万手,成交额3.33亿元。当日关注点交易信息汇总:8月13日主力资金净流入1120.77万元,占总成交额3.37%。股本股东变化:截至2026年7月31日,上海莱士股东户数为11.78万户,较7月20日减少3314户,减幅2.74%。户均持股数量由上期的5.44万股增加至5.6万股,户均持股市值为29.0万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400000868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","BK0239","BK0028","002252","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659845771","title":"上海莱士:截至2026年7月31日,公司股东总户数为117,773户","url":"https://stock-news.laohu8.com/highlight/detail?id=2659845771","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659845771?lang=zh_cn&edition=full","pubTime":"2026-08-13 09:12","pubTimestamp":1786583526,"startTime":"0","endTime":"0","summary":"证券之星消息,上海莱士(002252)08月12日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截止到7月31日公司股东人数是多少?谢谢上海莱士回复:感谢您的关注! 截至2026年7月31日,公司股东总户数为117,773户。 谢谢。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300007457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0028","BK0046","002252","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659904632","title":"股市必读:上海莱士新发布《关于第六届董事会第二十次(临时)会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659904632","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659904632?lang=zh_cn&edition=full","pubTime":"2026-08-13 01:49","pubTimestamp":1786556950,"startTime":"0","endTime":"0","summary":"关于召开2026年第二次临时股东会的通知上海莱士血液制品股份有限公司将于2026年8月31日召开2026年第二次临时股东会,会议由第六届董事会召集,现场会议地点为上海市奉贤区南桥新城展园路398号南郊宾馆。该事项已经董事会审计委员会审核并经第六届董事会第二十次(临时)会议审议通过,尚需提交公司2026年第二次临时股东会审议后生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300001251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0239","BK0028","BK0196","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658912998","title":"股市必读:上海莱士新发布《关于第六届董事会第二十次(临时)会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658912998","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658912998?lang=zh_cn&edition=full","pubTime":"2026-08-12 01:16","pubTimestamp":1786468608,"startTime":"0","endTime":"0","summary":"公司公告汇总:董事会审议通过续聘安永华明为2026年度会计师事务所,审计费用预计428万元,尚需提交8月31日召开的临时股东会审议。公司公告汇总:定于2026年8月31日召开2026年第二次临时股东会,股权登记日为8月25日。该事项已经董事会审计委员会审核并经第六届董事会第二十次(临时)会议审议通过,尚需提交公司2026年第二次临时股东会审议后生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200001535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","BK0239","BK0028","002252","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658161219","title":"上海莱士(002252)披露拟续聘2026年度会计师事务所公告,8月11日股价下跌0.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658161219","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658161219?lang=zh_cn&edition=full","pubTime":"2026-08-11 22:10","pubTimestamp":1786457445,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘,上海莱士报收于4.98元,较前一交易日下跌0.8%,最新总市值为328.32亿元。该股当日开盘5.02元,最高5.08元,最低4.96元,成交额达2.14亿元,换手率为0.65%。近日,上海莱士血液制品股份有限公司发布《关于拟续聘2026年度会计师事务所的公告》。公告显示,公司拟续聘安永华明会计师事务所为2026年度会计师事务所,负责公司财务报告及内部控制审计工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100038054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","002252","BK0196","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658670949","title":"股市必读:上海莱士(002252)8月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2658670949","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658670949?lang=zh_cn&edition=full","pubTime":"2026-08-10 01:00","pubTimestamp":1786294847,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘,上海莱士报收于5.04元,上涨2.86%,换手率1.09%,成交量72.03万手,成交额3.56亿元。董秘最新回复投资者: 董秘您好!请问截止7月31号,公司的股东人数是多少?截至2026年7月31日,公司股东总户数为117,773户。当日关注点交易信息汇总:8月7日主力资金净流入2385.44万元,占总成交额6.71%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002252","BK0046","BK0239","BK0196","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657612926","title":"上海莱士新提交“-”、“莱莱侠”等2件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2657612926","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657612926?lang=zh_cn&edition=full","pubTime":"2026-08-07 07:08","pubTimestamp":1786057707,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示,近日上海莱士血液制品股份有限公司新提交“-”、“莱莱侠”等2件商标注册申请。商标申请详情如下:今年以来上海莱士血液制品股份有限公司新申请注册商标10件,截止目前公司共持有注册商标74件,另有12件商标尚在注册申请中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700006107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","002252","BK0028","BK0239","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655870944","title":"上海莱士:公司7月推出的回购方案将全部用于注销并减少注册资本","url":"https://stock-news.laohu8.com/highlight/detail?id=2655870944","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655870944?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:52","pubTimestamp":1785415926,"startTime":"0","endTime":"0","summary":"证券之星消息,上海莱士07月29日在投资者关系平台上答复投资者关心的问题。谢谢上海莱士回复:关于股份回购:公司7月推出的回购方案将全部用于注销并减少注册资本,直接增厚每股净资产与每股收益。截至2025年末公司资金储备约28.4亿元,本次回购上限5亿元,不会挤占研发与运营资源。但公司并非原地踏步:创新药方面,全球首创品种SR604注射液I/II期关键数据表现良好,III期准备已同步启动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000037396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002252","BK0046","BK0239","BK0196","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655820492","title":"上海莱士(002252)7月20日股东户数12.11万户,较上期增加2.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655820492","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655820492?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:54","pubTimestamp":1785405284,"startTime":"0","endTime":"0","summary":"证券之星消息,近日上海莱士披露,截至2026年7月20日公司股东户数为12.11万户,较7月10日增加2386.0户,增幅为2.01%。在生物制品行业个股中,上海莱士股东户数高于行业平均水平,截至7月20日,生物制品行业平均股东户数为3.58万户。从股价来看,2026年7月10日至2026年7月20日,上海莱士区间涨幅为13.97%,在此期间股东户数增加2386.0户,增幅为2.01%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000028302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","BK0188","BK0196","BK0239","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655448398","title":"上海莱士:截至2026年7月20日,公司股东总户数为121,087户","url":"https://stock-news.laohu8.com/highlight/detail?id=2655448398","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655448398?lang=zh_cn&edition=full","pubTime":"2026-07-30 11:36","pubTimestamp":1785382593,"startTime":"0","endTime":"0","summary":"证券之星消息,上海莱士(002252)07月29日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好!请问截止7月20号,公司的股东人数是多少?谢谢上海莱士回复:感谢您的关注! 截至2026年7月20日,公司股东总户数为121,087户。 谢谢。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000014894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0239","002252","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653770428","title":"公司问答丨上海莱士:公司拥有SR604中国大陆、中国香港地区及中国台湾地区研发、商业化权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2653770428","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653770428?lang=zh_cn&edition=full","pubTime":"2026-07-24 15:35","pubTimestamp":1784878515,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","BK0046","BK0188","BK0196","002252","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653703956","title":"上海莱士:SR604抗体来自同一原始细胞株","url":"https://stock-news.laohu8.com/highlight/detail?id=2653703956","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653703956?lang=zh_cn&edition=full","pubTime":"2026-07-24 11:37","pubTimestamp":1784864247,"startTime":"0","endTime":"0","summary":"证券之星消息,上海莱士(002252)07月23日在投资者关系平台上答复投资者关心的问题。投资者提问:美国开始临床试验的SR604是不是和莱士的是同一款产品?如果不是,美国临床的SR604是否有使用莱士的专利授权?上海莱士回复:感谢您的关注!公司的SR604抗体是在海外转让的针对活化蛋白C的小鼠杂交瘤细胞株产生的鼠抗人活化蛋白C抗体的基础上进一步研究开发的产品,美国临床的SR604和公司项目同源,来自同一原始细胞株。公司拥有SR604中国大陆、中国香港地区及中国台湾地区研发、商业化权益。谢谢。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400016003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002252","BK0046","BK0239","BK0196","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653476543","title":"上海莱士(002252)披露SR604注射液II期临床试验登记进展,7月22日股价上涨0.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653476543","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653476543?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:07","pubTimestamp":1784729238,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘,上海莱士报收于5.18元,较前一交易日上涨0.78%,最新总市值为341.5亿元。该股当日开盘5.12元,最高5.2元,最低5.09元,成交额达4.35亿元,换手率为1.28%。上海莱士血液制品股份有限公司近日在国家药品监督管理局药物临床试验登记与信息公示平台登记了SR604注射液用于先天性凝血因子Ⅶ缺乏症的II期临床试验。SR604注射液为一种单克隆抗体制剂,此前已获准开展针对血友病A/B及先天性凝血因子Ⅶ缺乏症的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0188","BK0196","002252","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787716310888,"stockEarnings":[{"period":"1week","weight":0.002},{"period":"1month","weight":-0.0161},{"period":"3month","weight":-0.0472},{"period":"6month","weight":-0.2166},{"period":"1year","weight":-0.2983},{"period":"ytd","weight":-0.2197}],"compareEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":0.0197},{"period":"3month","weight":-0.0499},{"period":"6month","weight":-0.062},{"period":"1year","weight":0.0015},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海莱士血液制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"117418人(较上一季度减少0.30%)","perCapita":"56109股","listingDate":"2008-06-23","address":"上海市奉贤区望园路2009号","registeredCapital":"659267万元","survey":" 上海莱士血液制品股份有限公司的主营业务是血液制品的生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品。公司先后获评“上海市外商投资先进技术企业”“高新技术企业”,并设立“院士专家工作站”,彰显在技术研发与质量管控领域的领先地位;公司及旗下南岳生物先后斩获第九届上海市奉贤区区长质量奖金奖和“第八届湖南省省长质量奖”。","listedPrice":12.81},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海莱士,002252,上海莱士股票,上海莱士股票老虎,上海莱士股票老虎国际,上海莱士行情,上海莱士股票行情,上海莱士股价,上海莱士股市,上海莱士股票价格,上海莱士股票交易,上海莱士股票购买,上海莱士股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}